Resverlogix Corp. Cash Flow Conversion Efficiency
Resverlogix Corp. cash flow conversion efficiency. Based on the latest financial reports, Resverlogix Corp. (RVX) has a cash flow conversion efficiency ratio of 0.010x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-925.52K ≈ $-669.51K USD) by net assets (CA$-94.12 Million ≈ $-68.08 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Resverlogix Corp. (2001–2025)
Cash flow conversion efficiency of Resverlogix Corp. from 2001 to 2025. This chart illustrates how Resverlogix Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View RVX stock price for real-time trading data and today's change.
Resverlogix Corp. Cash Flow Conversion Ratio Explained
Resverlogix Corp. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Resverlogix Corp. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Resverlogix Corp. ranked by their cash flow conversion efficiency. Also see RVX company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ADS Maritime Holding Plc
OL:ADS
|
-0.043x |
|
YX Precious Metals Bhd
KLSE:0250
|
-0.028x |
|
Mexco Energy Corporation
NYSE MKT:MXC
|
0.045x |
|
Shivam Autotech Limited
NSE:SHIVAMAUTO
|
-0.527x |
|
Tandy Leather Factory Inc
NASDAQ:TLF
|
-0.070x |
|
Aciselsan Acipayam Seluloz Sanayi Ve Ticaret AS
IS:ACSEL
|
0.026x |
|
Daelim Trading
KO:006570
|
-0.034x |
|
Lodzia
TA:LODZ
|
0.018x |
Annual Cash Flow Conversion Efficiency for Resverlogix Corp. (2001–2025)
The table below shows the annual cash flow conversion efficiency of Resverlogix Corp. from 2001 to 2025. Review Resverlogix Corp. (RVX) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$-88.80 Million ≈ $-64.24 Million |
CA$-3.73 Million ≈ $-2.69 Million |
0.042x | -11.77% |
| 2024-12-31 | CA$-81.73 Million ≈ $-59.13 Million |
CA$-3.89 Million ≈ $-2.81 Million |
0.048x | +40.95% |
| 2023-12-31 | CA$-74.47 Million ≈ $-53.87 Million |
CA$-2.51 Million ≈ $-1.82 Million |
0.034x | -43.53% |
| 2022-12-31 | CA$-59.28 Million ≈ $-42.88 Million |
CA$-3.54 Million ≈ $-2.56 Million |
0.060x | -55.43% |
| 2021-12-31 | CA$-59.87 Million ≈ $-43.31 Million |
CA$-8.02 Million ≈ $-5.80 Million |
0.134x | +121392.30% |
| 2020-12-31 | CA$-39.90 Million ≈ $-28.86 Million |
CA$-4.40K ≈ $-3.18K |
0.000x | -99.96% |
| 2019-12-31 | CA$-64.11 Million ≈ $-46.38 Million |
CA$-17.34 Million ≈ $-12.55 Million |
0.271x | +15.07% |
| 2018-12-31 | CA$-207.72 Million ≈ $-150.26 Million |
CA$-48.83 Million ≈ $-35.33 Million |
0.235x | -21.73% |
| 2017-12-31 | CA$-83.68 Million ≈ $-60.53 Million |
CA$-25.13 Million ≈ $-18.18 Million |
0.300x | +34.58% |
| 2016-12-31 | CA$-101.57 Million ≈ $-73.47 Million |
CA$-22.67 Million ≈ $-16.40 Million |
0.223x | -41.21% |
| 2015-12-31 | CA$-56.43 Million ≈ $-40.82 Million |
CA$-21.42 Million ≈ $-15.50 Million |
0.380x | +229.32% |
| 2014-12-31 | CA$-73.73 Million ≈ $-53.33 Million |
CA$-8.50 Million ≈ $-6.15 Million |
0.115x | -44.80% |
| 2013-12-31 | CA$-63.22 Million ≈ $-45.73 Million |
CA$-13.20 Million ≈ $-9.55 Million |
0.209x | -78.75% |
| 2012-12-31 | CA$-29.50 Million ≈ $-21.34 Million |
CA$-29.00 Million ≈ $-20.98 Million |
0.983x | +111.21% |
| 2011-12-31 | CA$2.74 Million ≈ $1.98 Million |
CA$-24.03 Million ≈ $-17.38 Million |
-8.766x | -95.92% |
| 2010-12-31 | CA$4.30 Million ≈ $3.11 Million |
CA$-19.24 Million ≈ $-13.92 Million |
-4.474x | -8.91% |
| 2009-12-31 | CA$4.46 Million ≈ $3.23 Million |
CA$-18.34 Million ≈ $-13.26 Million |
-4.108x | -266.55% |
| 2008-12-31 | CA$11.61 Million ≈ $8.40 Million |
CA$-13.01 Million ≈ $-9.41 Million |
-1.121x | +68.96% |
| 2007-12-31 | CA$5.44 Million ≈ $3.94 Million |
CA$-19.65 Million ≈ $-14.21 Million |
-3.611x | -137.13% |
| 2006-12-31 | CA$-1.02 Million ≈ $-738.42K |
CA$-9.93 Million ≈ $-7.18 Million |
9.724x | +1749.37% |
| 2005-12-31 | CA$7.48 Million ≈ $5.41 Million |
CA$-4.41 Million ≈ $-3.19 Million |
-0.590x | -166.26% |
| 2004-12-31 | CA$9.84 Million ≈ $7.12 Million |
CA$-2.18 Million ≈ $-1.58 Million |
-0.221x | +35.03% |
| 2003-12-31 | CA$2.60 Million ≈ $1.88 Million |
CA$-885.04K ≈ $-640.23K |
-0.341x | +29.20% |
| 2002-12-31 | CA$942.21K ≈ $681.58K |
CA$-453.56K ≈ $-328.10K |
-0.481x | -1038.52% |
| 2001-12-31 | CA$259.64K ≈ $187.82K |
CA$-10.98K ≈ $-7.94K |
-0.042x | -- |
About Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID… Read more